FDA Grants Priority Review to BMS Skin Cancer Drug

Drug Industry Daily
A A
Bristol-Myers Squibb’s (BMS) BLA for melanoma treatment ipilimumab has received a priority review designation from the FDA.

To View This Article:

Login

Subscribe To Drug Industry Daily